Design and Evaluation of Chitosan films for Transdermal delivery of Glimepiride

  • Syed Ata Ur Rahman
  • Neeraj Sharma
Keywords: Glimepiride, transdermal, chitosan, penetration enhancers, cyclodextrins


Glimepiride is a third generation oral antidiabetic sulphonylurea drug frequently prescribed to patients of type 2 diabetes. However, its oral therapy is encountered with bioavailability problems due to its poor solubility leading to irreproducible clinical response, in addition to adverse effects like dizziness and gastric disturbances. As a potential for convenient, safe and effective antidiabetic therapy, the rationale of this study was to develop a transdermal delivery system for glimepiride. Chitosan polymer was utilized in developing transdermal films for glimepiride. Chitosan has film forming ability, bioadhesive and absorption enhancing properties. Aiming at optimizing the drug delivery and circumventing the skin barrier function, inclusion complexation of glimepiride with beta-cyclodextrin (β-CyD) as well as the use of several conventional penetration enhancers were monitored for augmenting the drug flux. The physical and mechanical properties of the prepared films were investigated using tensile testing, IR spectroscopy and X-ray diffractometry. Release studies revealed adequate release rates from chitosan films. Permeation studies through full thickness rat abdominal skin were conducted. High flux values were obtained from films comprising a combination of the drug with limonene and ethanol as well as from films containing glimepiride-β-CyD complex. In vivo studies on diabetic rats for selected formulae revealed a marked therapeutic efficacy sustained for about 48 hours. The above-mentioned results shed light on feasibility of utilizing chitosan as an effective, safe transdermal delivery system for glimepiride characterized by increased patient compliance and better control of the disease.


1. Kabadi, UM. Manag. Care, 2004, 13, 48.
2. Kouichi, I.; Masaki, W.; Youhei, N.; Takahiro, S.; Nobuki, T; Masahiko, T.; Hideyuki, K.; Kensuke, Y.; Masao, S., Susumu, K.;Takuya A.; Shigehiro, K. Diabetes Res. Clin. Pract., 2005, 68, 250.
3. Thummel, K.E. Adv. Drug Deliv. Rev., 1997, 27, 97.
4. Frick, A.; Moller H.; Wirbitzki, E. Eur. J. Pharm. Biopharm., 1998, 46, 305.
5. Massimo, M.B. Clin. Ther., 2003, 25, 799.
6. Profozic V.L.; Metelko, Z.L. Dis. Manag. Health Outcomes, 1998, 4, 29.
7. Barry, B. W. Eur. J .Pharm. Sci., 2001, 14, 101.
8. Panchagnula, R., Ind. J. Pharm., 1997, 29, 140.
9. Takahashi, Y.; Furuya, K.; Iwata, M.; Onishi, H.; Machida, Y.; Shirotake, S. Yakugaku Zasshi, 1997, 117, 1022.
10. Takahashi, Y.; Iwata, M.; Machida, Y. Yakugaku Zasshi, 2001. 121, 161.
11. Mutalik, S.; Udupa, N. J. Pharm. Sci., 2004, 93, 1577.
12. Sridevi, S.; Diwan, P.V.R. Pharmazie, 2002, 57, 632.
13. Mutalik, S.; Udupa, N. Pharmazie, 2002, 57, 838.
14. Ammar, H.O; Salama, H.A.; Ghorab, M.; El-Nahhas S.; Elmotasem, H. Curr. Drug Deliv., 2006, 3, 333.
15. Zhang, Y.; Xu, D.H.; Ma, Z.; Chen, Y.; Zhao, J.J; Xu, S.B. Yao Xue Xue Bao., 2004, 39, 640.
16. Chae, Su.Y.; Jang, Mi.K.; Nah, J.W. J. Control. Release, 2005, 102, 383.
17. Paul, W.; Sharma, C.P. S.T.P. Pharm. Sci., 2000,10, 5.
18. Illum, L., Pharm. Res., 1998, 15, 1326.
19. Ranaldi, G.; Marigliano, I.; Vespignani, I.; Perozzi, G.; Sambuy, Y. J. Nutr. Biochem., 2002, 13, 157.
20. Schipper, N.G.M.; Olsson, S.; Hoogstraate, J.A.; deBoer, A.G.; Varum, K.M.; Artursson, P. Pharm. Res., 1997, 14, 923.
21. Schipper, N.G.M.; Varum, K.M.; Stenberg, P.; Ocklind, G.; Lennernas, H.; Artursson, P. Eur. J. Pharm. Sci., 1999, 8, 335.
22. Zerrouka, N; Menninib, N.; Maestrellib, F.; Chemtoba, C.; Murab, P. Eur. J. Pharm. Biopharm., 2004, 57, 93.
23. Foldvari, M. Pharm.Sci. Technol. Today., 2000, 3, 417.
24. Ammar, H.O.; Salama, H.A.; Ghorab M.; Mahmoud, A.A. Int. J. Pharm., 2006, 309, 129.
25. Ammar, H.O.; El-Nahhas, S.A. Pharmazie, 1995, 50, 408.
26. Loftsson, T.; Bodor, N. Effect of cyclodextrins on percutaneous transport of drugs. In: Smith, E.W.; Maibach, H.I., Eds, Percutaneous Penetration Enhancers. Florida. CRC Press, Boca Raton, 1995, pp. 335.
27. Mastuda, H.; Arima, H. Adv. Drug Deliv. Rev., 1999, 36, 81.
28. Lopez, R.F.; Colett, J.H.; Bently, M.V. Int. J. Pharm., 2000, 200, 27.
29. Martin, A.; Bustamante, P.; Chun A.H.C. Physical Pharmacy: Physical Chemical Principles in Pharmaceutical Sciences (forth ed.), Lippincott Williams & Wilkins, 1993, pp. 260.
30. Uekema, K.; Horiuchi Y.; Kikuchi M. J. Incl. Phenom., 1988, 6, 167.
31. El-Sabbagh, S.H.; Hussain A.I.; Abd El-Ghaffar, M.A. Pigment & Resin Technol., 2005, 4, 203.
32. Shah, V.P.; Tymes, N.W.; Yamamoto, L.A.; Skelly, J.P. Int. J. Pharm., 1986, 32, 243.
33. Vogel, H.G.; Vogel, W.H. Drug Discovery and Evaluation: Pharmacological Assays. Berlin. Springer - Verlag, 1997, pp. 570.
34. Stepensky, D.; Friedman, M.; Srour, W.; Raz, I.; Hoffman, A., J. Control. Release, 2001, 71, 107.
35. Pepato, M.T.; Keller, E.H; Baviera, A.M.; Kettelhut, I.C.; Vendarmini, R.C. J. Ethnopharmacol., 2002, 81, 191.
36. Gabra, P.H.; Sirois, P. Eur. J. Pharm., 2005, 514, 61.
37. Ladriere, L.; Malaisse-Lagae, F.; Fuhlendorff, J.; Malaisse, W.J. Eur. J. Pharm., 1997, 335, 227.
38. Wagner, S.G., Fundamentals of Clinical Pharmacokinetics (first ed.), Drug Intelligence Publications Inc., Hamilton, Illinois, 1975, pp. 7.
39. Knapczyk, J. Int. J. Pharm., 1993, 93, 233.
40. Lai, H.M.; Padua, G.W. Cereal. Chem., 1997, 74, 771.
41. Wu, C.; McGinity, J.W. Int. J. Pharm., 1999, 177, 15.
42. Peppas, N.A.; Buri, P.A. J. Control. Release, 1985, 2, 257.
43. Ahmad Khan, T.; Peh, K. K.; Ching, H. S. Pharm. Pharmaceut. Sci., 2000, 3, 303.
44. Kurozumi, M.; Nambu, N.; Nagai, T. Chem. Pharm. Bull., 1975, 23, 3062.
45. Ozkana, Y.; Ataya, T.; Dikmena, N.; I
How to Cite
Ata Ur Rahman, S., and N. Sharma. “Design and Evaluation of Chitosan Films for Transdermal Delivery of Glimepiride”. Himalayan Journal of Health Sciences, Vol. 3, no. 4, Dec. 2018, pp. 13-25, doi:10.22270/ijist.v3i4.19.
Original Articles